{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-26-000006","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.787670+00:00","generated_at":"2026-05-16T00:09:21.973585+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Penumbra Q4 revenue $385.4M (+22.1%); operating income $59.2M; FY25 rev $1.4B (+17.5%)","bullets":["Revenue $385.4M for Q4, up 22.1% YoY (20.9% constant currency). US Thrombectomy $203.1M (+12.4%).","Gross margin 68.0% vs 66.8% a year ago; operating margin 15.4%.","Net income $47.3M; adjusted EBITDA $79.1M (20.5% margin).","Full year revenue $1,403.7M, up 17.5%; net income $177.7M; adjusted EBITDA $266.8M.","Embolization & access revenue grew 37.0% in Q4; international revenue up 27.7% (21.9% constant currency)."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-26-000006","json":"https://secwatch.observer/filing/0001321732-26-000006.json","markdown":"https://secwatch.observer/filing/0001321732-26-000006.md","text":"https://secwatch.observer/filing/0001321732-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173226000006/0001321732-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173226000006/pen-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:09:21.973585+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}